Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Sponsor
Boehringer Ingelheim
Study ID
NCT05262764
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • JARDIANCE® — DRUG
    Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS).

Study Details

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.

Key Dates

Start date
Apr 15, 2022
Status verified
Mar 2026
Primary completion
Jun 21, 2024
Completion
Jun 28, 2024

Study Design

Enrollment
1,200 participants (actual)

Arms

  • Arm: JARDIANCE®
    Patients in Japan with chronic heart failure who were prescribed JARDIANCE® tablets and who were never treated with Empagliflozin before enrolment. Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS). Patients were observed for up to 52 weeks after start of the treatment or until discontinuation of administration.

Primary Outcome Measure

Number of Subjects With Adverse Drug Reactions (ADRs) [ Time Frame: Up to 52 weeks ]

Related coverage on Hipa.ai

Related Studies